The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients.
Since 2003, we have grown into a network of more than 200 partner institutions that spans the globe, united in our pursuit of science for the people, driven by collaboration, not competition, and by medical needs, not profits. Together, we have delivered 8 new treatments that have saved millions of lives.
Now is the time to look ahead. This year, DNDi launches a new Strategic Plan 2021-2028, charting a journey to deliver 15 – 18 treatments by 2028.
In a world that is constantly changing, what can we do for neglected patients from Japan in the near future? What is needed for R&D partnerships? How can we deliver on our commitments to people whose diseases have been historically overlooked by the traditional R&D model?
To mark the launch of our new strategy, we were joined by a panel of passionate leaders and experts to explore what it will take to deliver medical solutions for neglected patients and build an R&D system that leaves no one behind.
- Dr Haruo Naito, KBE, Representative Corporate Officer and CEO, Eisai Co., Ltd.
- Prof. Kiyoshi Kita, Dean, School of Tropical Medicine and Global Health, Nagasaki University and Professor Emeritus, University of Tokyo
- Dr Hiroki Nakatani, Chair & Representative Director, GHIT Fund
- Dr Keizo Takemi, Member of the House of Councillors, Japan and Former Senior Vice Minister of Health, Labour and Welfare
- Dr Bernard Pécoul, Executive Director, DNDi
Moderator: Ms. Tomoko Sakota, Journalist, Former Senior Commentator, Japan Broadcasting Corporation (NHK)
Language: Japanese and English (simultaneous interpretation provided)